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Noonan syndrome and Turner syndrome
patients respond similarly to 4 years’
growth-hormone therapy: longitudinal
analysis of growth-hormone-naïve patients
enrolled in the NordiNet® International
Outcome Study and the ANSWER Program
Peter A. Lee1*, Judith L. Ross2,3, Birgitte Tønnes Pedersen4, Primoz Kotnik5, John A. Germak6
and Henrik T. Christesen7
Abstract
Background: Turner syndrome (TS) and Noonan syndrome (NS) are distinct syndromes associated with short
stature and other similar phenotypic features. We compared the responses to growth hormone (GH) therapy of TS
and NS patients enrolled in the NordiNet® International Outcome Study (IOS) or the American Norditropin Studies:
Web-Enabled Research (ANSWER) Program, which collect information on GH therapy in clinical practice.
Methods: Repeated-measures regression analysis was performed on change in height standard deviation score
(HSDS) and target-height-corrected HSDS, based on national normal references and treatment-naïve disease-specific
references. Models were adjusted for baseline age and HSDS, and average GH dose. The study population was
paediatric patients with TS and NS in the NordiNet® IOS and ANSWER Program. Longitudinal growth responses over
4 years were evaluated.
Results: In 30 NS patients (24 males; baseline age 8.39 ± 3.45 years) and 294 TS patients (7.81 ± 3.22 years), 4-year
adjusted ΔHSDS were +1.14 ± 0.13 and +1.03 ± 0.04, respectively (national references). Based on untreated,
disease-specific references, 4-year adjusted ΔHSDS for NS and TS were +1.48 ± 0.10 and +1.79 ± 0.04. The
analyses showed a significant increase in HSDS over time for both NS and TS (P < 0.0001). ΔHSDS in NS was
higher with younger baseline age; ΔHSDS in TS was higher for patients with younger baseline age and higher
GH dose.
Conclusions: NS and TS patients responded well and similarly over 4 years of GH treatment.
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Background
The genetic disorders Turner syndrome (TS) and Noonan
syndrome (NS) are distinct clinical conditions sharing
phenotypic similarities, including short stature [1–5].
TS affects at least one in 2500 live-born females [4].
Short stature is a prevalent feature, linked with haplo-
insufficiency of the short-stature homeobox-containing
(SHOX) gene [4]. TS girls usually achieve an adult
height ~20–21 cm shorter than otherwise healthy
women [3, 4]. The typical growth pattern is of growth
retardation, with slow growth initially during infancy,
subnormal growth rates in childhood, and absence of a
pubertal growth spurt. TS girls usually have a normal
pattern of GH secretion [4].
NS has a similar prevalence to TS (one in 1000–2500
live-born male and female births) [5]. Genetic mutations
are identifiable in 70–80 % of NS patients [6], with mis-
sense mutations on the protein tyrosine phosphatase
non-receptor type 11 gene (PTPN11) being the most fre-
quently identified in around 50 % [5]. Some 50–70 % of
NS patients have short stature [5]. The causes of poor
growth in NS are complex. GH-secretory dynamics and
insulin-like growth factor (IGF)-I levels in NS range
from deficient to normal, and may reflect the genotypic
heterogeneity of NS. Some NS patients have GH defi-
ciency (GHD). Usually, individuals with NS are born with
appropriate size for gestational age, but untreated children
only reach median adult heights of 162.5 cm for men and
153.0 cm for women (European cohorts), i.e., adult heights
averaging approximately –2 standard deviation scores
(SDS) from the reference population [5, 7, 8].
Treatment with recombinant human GH is recom-
mended for conditions associated with growth failure,
including TS and NS [1–5, 9]; however, considerable
variability of growth response to GH treatment has been
reported across diagnostic categories [10–15]. GH treat-
ment is not universally approved in short NS patients;
more long-term data on the growth response in these
patients are therefore merited.
Few studies have compared growth response to GH
treatment over time between the two syndromes, and
one published report comparing GH responses in TS
and NS patients (US National Cooperative Growth Study
[NCGS]) included NS patients with relatively high mean
age (11.6 years) at treatment start [16].
The NordiNet® International Outcome Study (IOS) is
a European-based registry (launched in 2006); the
American Norditropin Studies: Web-Enabled Research
(ANSWER) Program is a US-based registry (initiated in
2002). Both are long-term, observational studies de-
signed to collect information on effectiveness and safety
of the recombinant human GH product Norditropin®
([somatropin (rDNA origin) injection] Novo Nordisk,
Bagsværd, Denmark) in real-world practice [17].
We report on 4-year longitudinal growth outcomes in
paediatric NS and TS patients enrolled in the NordiNet®
IOS and ANSWER Program.
Methods
Study design
The study designs of the ongoing NordiNet® IOS
(ClinicalTrials.gov identifier: NCT00960128) and ANSWER
Program (ClinicalTrials.gov identifier: NCT00615953) are
described in detail elsewhere [17]. These non-
interventional, real-world data studies include patients
treated with Norditropin® as prescribed by their physicians.
The study population considered in this paper comprises
paediatric patients with a clinical diagnosis of NS or TS,
who were GH-treatment naïve at enrolment and prescribed
GH therapy with Norditropin®. The study databases use
web-based platforms (NordiNet® and NovoNet®) for data
capture in electronic Case Report Forms, providing auto-
matic validation at data entry. The studies were conducted
in accordance with the Declaration of Helsinki; patients
provided written, informed consent and data were
anonymised.
Data extraction and statistical analyses
In the NordiNet® IOS and ANSWER Program, all clinical
diagnoses were made by the treating physicians, according
to standard practice, who also entered all patient informa-
tion. Study protocol did not require genetic information.
This report included all patients with an NS or TS diagno-
sis who had complete 4-year longitudinal data.
Key demographic and clinical characteristics, captured
at baseline and during clinic visits, included: birth date;
sex and clinical diagnosis; patient’s height; parents’
height; bone age; age at GH treatment initiation; GH
dose and serum IGF-I levels [17]. Where available, pu-
bertal status data were gathered – prepubertal status
was defined based on clinical pubertal development
(Tanner breast stage B1; testicular volume < 4 mL).
Safety data were gathered, where available.
IGF-I values were measured locally and converted into
IGF-I SDS based on age- and sex-related normative ref-
erence values [18]. Baseline data were extracted within a
3-month window before GH treatment started, and
follow-up data at first-, second-, third- and fourth-year
(±3 months) visits.
NS and TS children’s growth responses, from start
through 4 years of GH treatment, were compared with
national reference growth charts and the untreated disease-
specific references for NS [7] and TS children [19–21]. The
latter are hereafter referred to as the ‘Ranke’ [7, 19], ‘Cabrol’
[20] and ‘Westerlaken’ [21] reference populations.
Attainment of genetic height potential, i.e., target-
height (TH)-corrected height standard deviation score
(HSDS), defined as HSDS minus target HSDS, during 4
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years of GH treatment was calculated (referred to here-
after as ‘TH-corrected’ data). Target height was deter-
mined by the corrected mid-parental height method
(adding/subtracting 6.5 cm for boys/girls, respectively).
Changes in HSDS (ΔHSDS) from baseline were calcu-
lated, and growth response in NS and TS children were
analysed and compared by a mixed linear model including
repeated-measures. This was performed for three different
responses: ΔHSDS based on national references; ΔHSDS
based on disease-specific references; and ΔHSDS based on
TH-corrected HSDS. To adjust for confounding factors,
the data-model included covariates of age at treatment
start, HSDS at baseline and average GH dose. For growth
data based on disease-specific population references for NS
and TS, HSDS and ΔHSDS are labelled ‘disease specific’.
Otherwise, growth data for HSDS and ΔHSDS are based
on national references of healthy children. Estimates ad-
justed for confounders are denoted ‘adjusted’.
Figures show estimated values (mean ± SE) obtained
by mixed linear models including repeated measures
and adjusted for confounders. Unadjusted estimates
(mean ± SD) for HSDS and ΔHSDS are included in the
Additional file 1: Table S1-S3.
Results
Patients
By November 2013, 30 NS patients (24 males, 6 females;
baseline age 8.39 ± 3.45 years) and 294 female TS patients
(baseline age 7.81 ± 3.22 years) had complete 4-year longi-
tudinal data. At baseline, NS and TS patients did not differ
significantly in age, HSDS and TH-corrected HSDS, bone
age or IGF-I SDS (Table 1, unadjusted data). Observed
baseline HSDS for NS was –2.64 ± 0.96 and for TS was
–2.67 ± 0.88. Using untreated disease-specific reference
populations (Ranke), baseline HSDS was –0.46 ± 0.89 in
NS vs +0.30 ± 0.99 in TS (P < 0.001); baseline HSDS in
TS was –0.20 ± 1.01 using the Westerlaken and –0.05 ±
1.03 using the Cabrol reference standard.
At baseline, 17 NS patients (mean age 7.61 years) were
prepubertal and two were pubertal/postpubertal (mean age
14 years). Information on pubertal status was missing for
11 NS patients. After 4 years’ GH treatment, 9 NS patients
remained prepubertal (baseline mean age 5.37 years,
chronological age 9.24 years); 12 were pubertal/postpuber-
tal (mean age at baseline 11.13 years, chronological age
14.78 years). Information was missing for 9 NS patients. At
baseline, 241 TS patients were prepubertal (mean age 7.73
years); 11 were pubertal/postpubertal (mean age 11.58
years). Information was missing for 42. After 4 years’ GH
treatment, 143 TS patients were prepubertal (baseline
mean age 5.84 years, chronological age 10.08 years); 106
were pubertal/postpubertal (baseline mean age 10.31
years, chronological age 14.29 years). Information was
missing for 45.
A limited number of GH stimulation tests were per-
formed at baseline – in 16 of 30 NS and 30 of 294 TS pa-
tients. Twenty-nine patients in the cohort met the criteria
for GHD (peak GH< 10 μg/L: 8 of 16 NS (mean 4.70 μg/L)
and 21 of 30 TS patients (mean 6.30 μg/L) (Table 1 for
baseline characteristics).
Table 1 Baseline demographic characteristics of Noonan syndrome (NS) and Turner syndrome (TS) patients with complete 4-year
longitudinal data (unadjusted data)
Baseline characteristic NS, mean ± SD TS, mean ± SD
All patients GHD subseta All patients GHD subseta
N, Sex (male:female) N = 30 (24:6) n = 8 (7:1) N = 294 (0:294) n = 21
Age, years (range) 8.39 ± 3.45 (2.38–14.29) 8.97 ± 4.19 (2.38–14.04) 7.81 ± 3.22 (0.51–15.23) 8.22 ± 3.21 (3.08–14.45)
HSDS −2.64 ± 0.96 −2.61 ± 0.81 −2.67 ± 0.88 −2.84 ± 0.53
HSDS (Ranke)b [7, 19] −0.46 ± 0.89 −0.43 ± 0.85 0.30 ± 0.99 −0.07 ± 0.67
HSDS (Westerlaken) [21] NA NA −0.20 ± 1.01 −0.53 ± 0.71
HSDS (Cabrol) [20] NA NA −0.05 ± 1.03 −0.39 ± 0.70
Target HSDS −0.43 ± 0.83 −0.81 ± 0.75 (n = 6) −0.24 ± 1.02 −0.56 ± 0.89
TH-corrected HSDSc −2.19 ± 1.14 −1.70 ± 1.19 (n = 6) −2.46 ± 1.16 −2.27 ± 1.10
Bone age, years 6.92 ± 3.58 6.96 ± 4.92 (n = 6) 6.72 ± 3.03 7.56 ± 3.12 (n = 12)
Bone age – chronological age −1.61 ± 1.22 −2.08 ± 1.17 (n = 6) −1.31 ± 1.12 −1.49 ± 1.07 (n = 12)
Father’s height (cm) 176.19 ± 7.38 173.78 ± 6.71 (n = 6) 176.94 ± 7.89 172.85 ± 8.05
Mother’s height (cm) 161.53 ± 8.49 158.08 ± 4.96 (n = 6) 163.57 ± 6.96 162.18 ± 6.93
IGF-I SDS −1.42 ± 1.45 (n = 19) −2.52 ± 1.27 (n = 5) −0.89 ± 1.51 (n = 147) −1.21 ± 1.28 (n = 11)
GHD Growth hormone deficiency, HSDS Height standard deviation score, NA Not applicable, TH Target height, SDS Standard deviation score
aGHD defined by GH peak < 10 μg/L
bHSDS (Ranke) NS vs TS mean difference –0.76 (95% confidence interval –1.13, –0.39); P < 0.001
cTH-corrected HSDS refers to attainment of genetic height potential, i.e., parental-height-corrected HSDS – defined as HSDS minus target HSDS, during 4 years of
GH treatment
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Mean cumulative GH dose over 4 years was similar
for NS and TS patients (48.85 ± 11.18 μg/kg/day and
47.64 ± 10.52 μg/kg/day, respectively). An increase in
mean GH dose was observed over time in NS patients
compared with baseline (P = 0.0478); no significant
change occurred in TS patients (Table 2).
Growth responses
In NS patients, HSDS values based on normal national ref-
erences were lower than TH-corrected HSDS values
(Fig. 1a) (Additional file 1: Table S1 for unadjusted esti-
mated means for HSDS). Baseline HSDS (mean ± SE) was
–2.59 ± 0.09, increasing to –1.48 ± 0.09 at year 4. Using the
Ranke NS reference, baseline HSDS was –0.39 ± 0.07, in-
creasing to 1.05 ± 0.07 after 4 years’ GH treatment.
TH-corrected ΔHSDS and ΔHSDS were almost iden-
tical, while disease-specific ΔHSDS values based on the
Ranke NS reference population were higher than
ΔHSDS and TH-corrected ΔHSDS (Fig. 1b) (Additional
file 1: Table S2 for unadjusted ΔHSDS estimates). The
ΔHSDS (mean ± SE) was 0.42 ± 0.06 at year 1, increasing
to 1.14 ± 0.13 at year 4. The disease-specific Ranke
ΔHSDS (mean ± SE) was 0.61 ± 0.06 at year 1, increasing
to 1.48 ± 0.10 at year 4.
Figure 2 depicts HSDS data for the TS patients. HSDS
and TH-corrected HSDS values were similar (Fig. 2a)
(Additional file 1: Table S1 for unadjusted estimated
means). Baseline HSDS (mean ± SE) was –2.67 ± 0.03, in-
creasing to –1.65 ± 0.03 at year 4. Baseline HSDS (mean
± SE) based on the Ranke TS reference was 0.30 ± 0.03,
increasing to 2.09 ± 0.03 after 4 years’ GH treatment.
Similar trends were observed using the Cabrol TS and
Westerlaken TS references.
The ΔHSDS values based on disease-specific TS refer-
ence values were greater than the ΔHSDS and TH-
corrected ΔHSDS based on normal population references
(Fig. 2b, Additional file 1: Table S2). The ΔHSDS (mean ±
SE) was 0.50 ± 0.03 at year 1, increasing to 1.03 ± 0.04 at
year 4. The disease-specific Ranke ΔHSDS (mean ± SE)
was 0.74 ± 0.02 at year 1, and 1.79 ± 0.04 at year 4. Using
the Westerlaken reference, mean ± SE ΔHSDS was 0.78
± 0.02 at year 1, and 1.93 ± 0.04 at year 4. Mean ± SE
ΔHSDS (Cabrol) for TS was similar: 0.76 ± 0.02 at year
1, and 1.86 ± 0.04 at year 4.
NS and TS patients responded similarly to GH therapy
over time (Fig. 3a and b). Figure 3a provides the HSDS esti-
mated means ± SE per indication based on the normal
national references adjusted for age at treatment start,
HSDS at baseline and average GH dose. The adjustment
only changed the values marginally from the unadjusted,
crude data (Additional file 1: Table S1). Figure 3b depicts
the estimated means (± SE) for ΔHSDS from baseline to 4-
year follow-up for each indication. This figure illustrates
the similar response in the NS and TS patients; no sig-
nificant difference between the indications was found
(P = 0.6281). The adjustment changed the values only
marginally (Additional file 1: Table S2).
Disease-specific ΔHSDS (Ranke) from baseline
showed a significant increase from baseline per visit-
year for each indication (NS: years 1–2 and years 2–3
[P < 0.0001], and years 3–4 [P = 0.0271]; TS: years 1–2,
Table 2 Mean daily GH dose in Noonan syndrome (NS) and
Turner syndrome (TS) patients over 4 years of GH treatment
NS TS
GH dose μg/kg/day GH dose μg/kg/day
Mean ± SD (n) Mean ± SD (n)
Baseline 44.32 ± 9.63 (27) 48.24 ± 13.20 (282)
Year 1 49.33 ± 11.82 (30) 48.20 ± 12.03 (286)
Year 2 50.86 ± 12.19 (27) 47.90 ± 12.41 (287)
Year 3 50.46 ± 13.04 (28) 47.47 ± 13.57 (288)
Year 4 49.78 ± 13.56 (27) 46.50 ± 12.90 (267)
Fig. 1 a Comparison of adjusted estimated means of Noonan
syndrome (NS) height standard deviation score (HSDS) references
(± SE): target height (TH)-corrected HSDS values, normal-height
standard deviation score values, and HSDS values based on the
Ranke reference [19]. b Comparison of adjusted estimated means
of change in NS HSDS references (±SE): TH-corrected and normal
ΔHSDS, and ΔHSDS values based on Ranke reference [19]
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years 2–3, and years 3–4 [all P < 0.0001]). Data analysis
and modelling using the reference populations Westerlaken
and Cabrol showed similar trends to the findings based on
the Ranke reference population assessments (data not
shown).
Additional analysis of ΔHSDS adjusting for baseline age,
HSDS at baseline and average relative GH dose confirmed
no difference between linear growth responses to GH
therapy at any visit according to indication (TS or NS)
(P > 0.05). Further analysis determined that baseline age
and years on treatment had a significant impact on the
change in HSDS based on the normal national reference
in NS patients (P = 0.0037 and P < 0.0001, respectively),
while all the modelled parameters (baseline HSDS, age at
baseline, years on treatment and average GH dose) had a
significant effect on responses in TS patients (P < 0.0001,
P < 0.0001, P < 0.0001 and P = 0.0265, respectively; param-
eter estimates not shown).
Percentages of patients in the NS and TS cohorts with
HSDS within and below the normal range at baseline
and each year of follow-up are shown in Table 3. At
baseline, 80 % of NS and 82 % of TS patients were below
Fig. 2 a Comparison of adjusted estimated means of Turner
syndrome (TS) height standard deviation score (HSDS) references
(± SE): target height (TH)-corrected HSDS values, normal-height
standard deviation score values, and HSDS values based on the
reference populations of Ranke [19], Cabrol [20] and Westerlaken
[21]. b Comparison of adjusted estimated means of change in TS
HSDS references (± SE): TH-corrected and normal ΔHSDS, and
ΔHSDS values based on the reference populations of Ranke [19],
Cabrol [20] and Westerlaken [21]
Fig. 3 a Adjusted estimated means of height standard deviation
score (HSDS; ± SE) by indication and visit year; adjusted for age at
treatment start, HSDS at baseline, and average GH dose. b Adjusted
estimated means of the change in HSDS, ΔHSDS (± SE) from
baseline by indication and visit year; adjusted for age at treatment
start, HSDS at baseline and average GH dose
Table 3 Patients with height below/within normal ranges by
indication
Noonan syndrome patients Turner syndrome patients
HSDS < –2 HSDS > –2 HSDS < –2 HSDS > –2
n (%) n (%) n (%) n (%)
Baseline 24 (80) 6 (20) 240 (82) 54 (18)
Year 1 16 (53) 14 (47) 166 (56) 128 (44)
Year 2 15 (50) 15 (50) 127 (43) 167 (57)
Year 3 9 (30) 21 (70) 113 (38) 181 (62)
Year 4 7 (23) 23 (77) 102 (35) 192 (65)
HSDS Height standard deviation score
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–2 HSDS; by year 4, this decreased to 23 and 35 %,
respectively.
Analysis of change in IGF-I SDS, adjusted for baseline
IGF-I SDS, age at treatment start and average GH dose,
showed no significant differences in change in IGF-I
SDS over time between the two patient populations
(Additional file 1: Table S3).
Safety data
The following adverse events were reported for the study
population included in this paper. One patient with TS,
enrolled in 2006, showed progression in her scoliosis in
2010. In another TS patient, four concurrent events
were reported (headache, adenoidectomy, paracentesis,
tonsillectomy), with only headache considered possibly
related to GH treatment. Other events reported in indi-
vidual TS patients included epiphysiolysis observed
after 6.5 years on treatment (considered probably treat-
ment related, with a dose reduction made in therapy), a
case of osteomyelitis after 9 years on treatment and a
case of developmental glaucoma after 2.5 years on treat-
ment (all considered possibly treatment related). A case
of cardiac failure in a TS patient after 7 years on treat-
ment was considered unlikely related to GH treatment
and a case of genital haemorrhage, after 4 years’ treat-
ment in another TS patient, was of unknown cause.
One NS patient reported two episodes of headache after
1 year of treatment, which were both considered treat-
ment related.
Discussion
The NordiNet® IOS and ANSWER Program data on
long-term outcomes for patients with NS and TS dem-
onstrate that the 2 patient groups responded well and
similarly during 4 years’ GH treatment – measured by
mean ΔHSDS and TH-corrected ΔHSDS based on nor-
mal national references.
Choice of reference population for growth in TS and
NS patients is important to the interpretation of the
magnitude of the growth response, with a mean 4-year
adjusted ΔHSDS varying from +1.14 (normal reference)
to +1.48 (Ranke) in NS patients, and from +1.03 (normal
reference) to +1.93 (Westerlaken) in TS patients. Effect-
iveness of treatment was similar, whichever disease-
specific reference population was applied to TS, attesting
to the robustness of our results.
Mean heights in untreated NS follow the third per-
centile during the first years of life, generally declining
further at the normal age of puberty onset [7, 19, 22]. In
45 adult NS patients, spontaneous height gain from age
8 years reached +0.57 SDS in boys and +1.00 SDS in
girls, using the Prader reference, and was interpreted as
the result of delayed puberty in NS [23].
Short-term GH therapy increases growth velocity, while
longer therapy results in more modest gains in adult height
[1, 2, 5]. Much of the data on GH treatment in NS come
from observational studies, in which GH therapy has
been commonly initiated at an older age (often aged 10
years when HSDS may be as low as –3.0), using lower
GH doses than those typically recommended for TS [8,
15, 16, 24, 25]. Preliminary data from the ANSWER Pro-
gram reported that, in NS subjects with mean baseline age
of 9.2 years, GH treatment for 4 years resulted in mean
ΔHSDS of +1.33 (from –2.65 to –1.32), with no gender dif-
ferences, for patients receiving a mean dose of 47 μg/kg/
day at baseline and 59 μg/kg/day at year 4 [8].
The NordiNet® IOS and ANSWER Program data for 4
years of longitudinal therapy presented here demonstrate
a mean ΔHSDS of +1.14 at 4 years’ treatment in NS pa-
tients. This analysis compares favourably with a study in
which a mean ΔHSDS of +0.8 (from –2.7 to –1.9 SDS)
was reported after 3 years of GH treatment [26]. In com-
parison, mean baseline HSDS in a group of eight control
NS patients not treated with GH was –2.7, with a mean
HSDS of –2.4 at year 3 [26]. In our NS patients, the
mean adjusted ΔHSDS was +1.00 at year 3 and +1.14 at
year 4.
Although not directly comparable, due to a shorter
treatment period and younger age at treatment start, our
4-year growth response data in NS patients with a mean
age of 8.39 years at enrolment appears to be in line with
those reported in the NCGS, which included 65 patients
who had a mean age of 11.6 years at enrollment, and
were treated with a mean GH dose of 0.33 mg/kg/week
(0.047 mg/kg/day). In patients achieving near adult
height, the NCGS reported an increase of +1.4 in HSDS
(from –3.5 to –2.1) after a mean duration of 5.6 years of
GH treatment, whereas in the total NS patient group, an
increase of +1.2 in HSDS (from –3.2 to –2.0) was
achieved after a mean duration of 5.3 years of GH treat-
ment [16].
In our study, we found more robust growth re-
sponses in NS patients than those reported from the
Kabi International Growth Study (KIGS) database, in
which a 3-year longitudinal prepubertal cohort of 73
NS patients (median age 7.7 years at start of therapy)
had a total increase in HSDS of +0.8 after 3 years (in-
crement of +0.54, +0.13 and +0.13 in years 1, 2 and 3,
respectively), compared with the ΔHSDS of +1.00 at
year 3 in the current study [13].
Although it is unclear whether responses to GH therapy
may be influenced by the genetic causes of NS, it has been
suggested that the 50 % of NS children with PTPN11 gene
mutations show reduced responses to GH therapy com-
pared with those with other mutations [8, 24, 27–31]. Due
to the observational nature of our studies, in which genetic
data were not prospectively collected for NS patients, it was
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not possible to analyse our dataset according to patient
genotype.
We observed that, based on TH SDS, parental heights for
NS patients may differ more from the normal population
than is the case for TS parental heights. As adults with NS
are often fertile, this may suggest that some parents of NS
patients may have undiagnosed NS.
The NordiNet® IOS and ANSWER Program 4-year data
also highlight the benefits of long-term GH therapy in
girls with TS, and add to the body of evidence on the ef-
fects of GH therapy on growth and final height achieve-
ment in TS patients, including recent reports suggesting
good growth responses to GH in TS girls, even when
treatment is not initiated until the age of 12 years [32–35].
Previous reports from the ANSWER Program suggest
that gains in height in TS patients during short-term GH
treatment are highly predictive of longer-term results. In
one report, the continuation of GH treatment for ≥ 3 years
resulted in 62.3 % of the TS patients achieving an HSDS
within the normal population range [32]. Our study in-
cluded 294 TS patients with a relatively young mean age of
7.81 years at baseline, with 65 % of patients achieving nor-
mal HSDS at year 4. This was not a final adult height in
our cohort, so more may achieve normal height SDS with
ongoing treatment.
Despite almost identical proportions of NS and TS pa-
tients with HSDS above –2 at baseline (20 and 18 %, re-
spectively), 77 % of NS, but only 65 % of TS patients, were
above –2 for HSDS after 4 years. This may be attributed to
the observed increase in mean GH dose in NS patients
from baseline to year 4. In addition, the covariate modelling
analysis showed a significant effect of average GH dose on
growth response in TS patients. These findings further sup-
port safe treatment optimization, including individualized
GH dose titration consistent with currently approved prod-
uct labels.
We observed that NS patients responded well to
long-term GH therapy and showed linear growth com-
parable to that in GH-treated TS patients. This may
provide evidence to challenge the belief that NS
patients may be less responsive to GH therapy, or show
initial responses that wane over time. The dose and
young age at initiation of GH therapy may have con-
tributed to the good growth responses observed for NS
patients in our study.
Our study included baseline measures of GH and
assessed IGF-I levels during GH treatment in a small pro-
portion of patients; the results suggest no differences in
change in IGF-I over time in both populations.
Strengths of this analysis include the real-world and lon-
gitudinal nature of the study, collecting data from many
TS and NS patients in several countries and allowing for
longer follow-up than may be possible in a clinical-trial
setting. Other strengths include use of disease-specific
references and the application of a model adjusting for
confounding factors. This cohort includes NS patients
who started treatment at a younger age than is typically
reported in the literature.
The observational nature of the NordiNet® IOS and
ANSWER Program data limits analysis of the outcomes,
particularly regarding assessment of outcomes according
to genetic diagnoses of NS and TS, and analysis of data in
relation to the pubertal status of patients during the study.
Likewise, the limited number of GH stimulation tests
means it is not possible to determine the differential pro-
portion of NS and TS patients with GHD and the impact
of GHD on results. The data allow for a comparison of
outcomes for TS and NS patients but the smaller sample
size for NS may hamper the ability to see year-on-year dif-
ferences as clearly as were noted in the TS cohort.
Conclusions
In conclusion, the NordiNet® IOS and ANSWER Program
4-year data demonstrate that, in real-world clinical prac-
tice, NS and TS patients can achieve good long-term re-
sponses to GH therapy, and responded similarly to 4 years
of GH therapy. The 4-year data show a significant increase
in HSDS over time for both NS and TS patients, measured
by mean ΔHSDS and TH-corrected ΔHSDS based on nor-
mal national reference values and mean ΔHSDS based on
disease-specific references. In both populations, the ΔHSDS
was higher for patients with younger baseline age. The data
add to understanding of the long-term responses to GH
therapy. Notably, the 4-year period reported from the inter-
national cohort of NS and TS patients in this study is lon-
ger than typical patient follow-up in clinical studies, thus
complementing and supplementing current knowledge. In
addition, patients in clinical studies are often older at treat-
ment outset than described in our dataset. Thus our report
demonstrates growth benefits from early treatment initi-
ation and continuing GH treatment in both NS and TS
patients as might occur in everyday clinical practice.
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